

SUPPLEMENTARY TABLES

Table S2. Treatment-emergent changes in clinical laboratory parameters.

Treatment-emergent change from normal baseline value to abnormal value in evaluable patients	AZD8601 3 mg (<i>n</i> = 7), <i>n/n</i> (%)	Placebo (<i>n</i> = 4), <i>n/n</i> (%)
Hematology		
Leucocytes, 10 ⁹ /L	Increase: 3/6 (50.0)	Increase: 2/4 (50.0)
Neutrophils, 10 ⁹ /L	Increase: 2/5 (40.0)	Increase: 1/4 (25.0)
Lymphocytes, 10 ⁹ /L	Increase: 1/5 (20.0) Decrease: 3/5 (60.0)	0/4 (0)
Monocytes, 10 ⁹ /L	Increase: 1/5 (20.0)	Increase: 1/4 (25.0)
Eosinophils, 10 ⁹ /L	Increase: 1/5 (20.0)	Decrease: 1/4 (25.0)
Basophils, 10 ⁹ /L	Increase: 1/5 (20.0)	0/4 (0)
Hemoglobin, g/L	Decrease: 5/6 (83.3)	Decrease: 3/4 (75.0)
Erythrocyte volume fraction, ratio	Decrease: 5/6 (83.3)	Decrease: 4/4 (100)
Erythrocyte mean cell volume, fL	Increase: 1/6 (16.7)	0/4 (0)
Mean cell hemoglobin, pg	0/6 (0)	0/4 (0)
Mean cell hemoglobin concentration, pg	0/6 (0)	0/4 (0)
Reticulocytes, 10 ⁹ /L	Increase: 2/5 (40.0)	0/3 (0)
Platelets, 10 ⁹ /L	Increase: 1/6 (16.7) Decrease: 3/6 (50.0)	Increase: 1/4 (25.0) Decrease: 1/4 (25.0)
Coagulation		
Prothrombin complex, international normalized ratio	0/4 (0)	0/4 (0)
Activated partial thromboplastin time, s	0/4 (0)	Increase: 2/4 (50.0) Decrease: 1/4 (25.0)
Fibrinogen, g/L	Increase: 3/3 (100)	Increase: 3/3 (100)
Biochemistry		
Sodium, mmol/L	Decrease: 1/6 (16.7)	Decrease: 1/4 (25.0)
Potassium, mmol/L	Increase: 1/6 (16.7) Decrease: 1/6 (16.7)	0/4 (0)
Urea, mmol/L	0/4 (0)	0/4 (0)
Creatinine, μmol/L	0/5 (0)	Increase: 1/4 (25.0)
Albumin, g/L	Decrease: 3/5 (60.0)	Decrease: 3/4 (75.0)
Calcium, mmol/L	Decrease: 2/5 (40.0)	Decrease: 4/4 (100)
Phosphate, mmol/L	Decrease: 2/4 (50.0)	Decrease: 2/4 (50.0)
Alkaline phosphatase, ukat/L	Increase: 1/5 (20.0)	Decrease: 1/4 (25.0)
Alanine aminotransferase, ukat/L	0/5 (0)	Increase: 1/4 (25.0)
Aspartate aminotransferase, ukat/L	0/5 (0)	Increase: 1/4 (25.0)
Total bilirubin, μmol/L	Increase: 1/5 (20.0)	0/4 (0)